10 November, 2021

Nanexa publishes interim report for January – September 2021

Substantial orders and pause in the NEX-18 study

25 October, 2021

Nanexa initiates complementary preclinical studies

Nanexa AB today announces that the company has initiated complementary preclinical studies to investigate what caused the moderate skin reactions that occurred in the company’s phase I study with NEX-18, a depot formulation of 5-azacitidine.


11 november, 2021

Redeye Life Science Day, VD David Westberg presenterar

10 november, 2021

Webcast och frågestund med VD David Westberg och styrelseledamot Bengt Gustavsson